Hyaluronic Acid and PLLA Formulations
The Aphorage Gloryal portfolio brings together cross-linked hyaluronic acid, a combined HA and PLLA formulation, and micro cross-linked HA. Explore their differences and request technical information to assess the range for your market.
Cross-Linked Hyaluronic Acid
Volume Plus and Complete contain cross-linked sodium hyaluronate. Volume Plus has an HA concentration of 24 mg/ml, while Complete contains 20 mg/ml and is described as biphasic in the product catalogue.
These formulations have distinct roles within the professional portfolio. Review each product’s composition and specifications when assessing the range for your market.
Combined HA and PLLA in RePLLAy
RePLLAy combines cross-linked sodium hyaluronate with poly-L-lactic acid (PLLA) microspheres. This combined composition distinguishes it from the HA-only formulations in the Aphorage Gloryal range.
For professional assessment, request the current product documentation covering composition, intended use and the clinical information available for the proposed market.
Micro Cross-Linked HA in Stimulate
Stimulate contains micro cross-linked sodium hyaluronate at 20 mg/ml. Within the portfolio, it is positioned for skin hydration and rejuvenation. Its formulation does not contain PLLA according to the supplied product catalogue.
Consult the individual product information to assess its specifications and its place alongside the other formulations in the range.
Understanding the HA and PLLA Combination
A formulation overview for RePLLAy: two components to understand, followed by product-specific professional assessment.
01
Cross-Linked HA
The HA component in RePLLAy is cross-linked sodium hyaluronate. HA-based fillers are used in aesthetic medicine for volume correction; product-specific uses should be checked in the current documentation.
02
PLLA Microspheres
RePLLAy also contains poly-L-lactic acid microspheres. PLLA is used in aesthetic formulations for collagen stimulation; this does not establish a fixed clinical timeline for every product.
03
Professional Assessment
Review the current RePLLAy technical and clinical information before assessing its suitability for your market. Intended use, expected response and supporting evidence must be evaluated for the specific product.
This is a formulation overview, not a treatment protocol or a guaranteed results timeline. Consult the current product documentation for intended use, precautions and product-specific evidence.
Technical Information for Your Market
Assessing Aphorage Gloryal for your distribution network? Tell RAMCODE about your company, your territory and the products you are interested in.
Request current product specifications and discuss the documentation available for professional assessment in your market. Product availability and commercial conditions are reviewed according to the proposed territory and applicable requirements.
Distribution & Professional Enquiries